Skip to main content
Top
Published in: Annals of Surgical Oncology 5/2018

01-05-2018 | Endocrine Tumors

Impact of Micro- and Macroscopically Positive Surgical Margins on Survival after Resection of Adrenocortical Carcinoma

Authors: Kevin L. Anderson Jr., MHS, Mohamed A. Adam, MD, Samantha M. Thomas, MS, Linda Youngwirth, MD, Michael T. Stang, MD, Randall P. Scheri, MD, Sanziana A. Roman, MD, Julie A. Sosa, MD, MA

Published in: Annals of Surgical Oncology | Issue 5/2018

Login to get access

Abstract

Purpose

Adrenocortical carcinoma (ACC) is a rare, aggressive cancer; complete surgical resection offers the best chance for long-term survival. The impact of surgical margin status on survival is poorly understood. Our objective was to determine the association of margin status with survival.

Methods

Patients with ACC were identified from the National Cancer Data Base, 1998–2012, and stratified based on surgical margin status (negative vs. microscopically positive [+] vs. macroscopically [+]). Univariate/multivariate regression/survival analyses were utilized to determine factors associated with margin status and overall survival (OS).

Results

A total of 1553 patients underwent surgery at 589 institutions: 86% had negative, 12% microscopically (+), and 2% macroscopically (+) margins. Those with microscopically (+) and macroscopically (+) margins more often received adjuvant chemotherapy (39.4% macroscopically (+) vs. 38.5% microscopically (+) vs. 25.2% negative margins, p < 0.001). For unadjusted analysis, there was a significant difference in OS between the groups (log-rank p < 0.001), with median survival times of 58 months (95% confidence interval [CI] 49–66) for those with negative margins, 22 months (95% CI 18–34) microscopically (+), and 14 months (95% CI 6–27) macroscopically (+) margins. After adjustment, both microscopically (+) (HR 1.76, p < 0.001) and macroscopically (+) (HR 2.10, p = 0.0019) margin status were associated with compromised survival.

Conclusions

Having micro- or macroscopically (+) margin status after ACC resection is associated with dose-dependent compromised survival. These results underscore the importance of achieving negative surgical margins for optimizing long-term patient outcomes.
Literature
1.
go back to reference Livhits M, Li N, Yeh MW, Harari A. Surgery is associated with improved survival for adrenocortical cancer, even in metastatic disease. Surgery. 2014;156:1531–40; discussion 1540-1.CrossRefPubMedPubMedCentral Livhits M, Li N, Yeh MW, Harari A. Surgery is associated with improved survival for adrenocortical cancer, even in metastatic disease. Surgery. 2014;156:1531–40; discussion 1540-1.CrossRefPubMedPubMedCentral
2.
go back to reference Fassnacht M, Johanssen S, Quinkler M, et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer. 2009;115:243–50.CrossRefPubMed Fassnacht M, Johanssen S, Quinkler M, et al. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer. 2009;115:243–50.CrossRefPubMed
3.
go back to reference Gratian L, Pura J, Dinan M, et al. Treatment patterns and outcomes for patients with adrenocortical carcinoma associated with hospital case volume in the United States. Ann Surg Oncol. 2014;21:3509–14.CrossRefPubMedPubMedCentral Gratian L, Pura J, Dinan M, et al. Treatment patterns and outcomes for patients with adrenocortical carcinoma associated with hospital case volume in the United States. Ann Surg Oncol. 2014;21:3509–14.CrossRefPubMedPubMedCentral
4.
go back to reference Grubbs EG, Callender GG, Xing Y, et al. Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane. Ann Surg Oncol. 2010;17:263–70.CrossRefPubMed Grubbs EG, Callender GG, Xing Y, et al. Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane. Ann Surg Oncol. 2010;17:263–70.CrossRefPubMed
5.
6.
go back to reference Lee JE, Berger DH, el-Naggar AK, et al. Surgical management, DNA content, and patient survival in adrenal cortical carcinoma. Surgery. 1995;118:1090–8.CrossRefPubMed Lee JE, Berger DH, el-Naggar AK, et al. Surgical management, DNA content, and patient survival in adrenal cortical carcinoma. Surgery. 1995;118:1090–8.CrossRefPubMed
7.
8.
go back to reference Ayala-Ramirez M, Jasim S, Feng L, et al. Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur J Endocrinol. 2013;169:891–9.CrossRefPubMedPubMedCentral Ayala-Ramirez M, Jasim S, Feng L, et al. Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur J Endocrinol. 2013;169:891–9.CrossRefPubMedPubMedCentral
9.
go back to reference Ronchi CL, Kroiss M, Sbiera S, et al. EJE prize 2014: current and evolving treatment options in adrenocortical carcinoma: where do we stand and where do we want to go? Eur J Endocrinol. 2014;171:R1–11.CrossRefPubMed Ronchi CL, Kroiss M, Sbiera S, et al. EJE prize 2014: current and evolving treatment options in adrenocortical carcinoma: where do we stand and where do we want to go? Eur J Endocrinol. 2014;171:R1–11.CrossRefPubMed
10.
go back to reference Bilimoria KY, Shen WT, Elaraj D, et al. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer. 2008;113:3130–6.CrossRefPubMed Bilimoria KY, Shen WT, Elaraj D, et al. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer. 2008;113:3130–6.CrossRefPubMed
11.
go back to reference Kendrick ML, Lloyd R, Erickson L, et al. Adrenocortical carcinoma: surgical progress or status quo? Arch Surg. 2001;136:543–9. Kendrick ML, Lloyd R, Erickson L, et al. Adrenocortical carcinoma: surgical progress or status quo? Arch Surg. 2001;136:543–9.
12.
go back to reference Abdel-Wahab M, El-Husseiny TS, El Hanafy E, et al. Prognostic factors affecting survival and recurrence after hepatic resection for hepatocellular carcinoma in cirrhotic liver. Langenbeck’s Arch Surg. 2010;395:625–32.CrossRef Abdel-Wahab M, El-Husseiny TS, El Hanafy E, et al. Prognostic factors affecting survival and recurrence after hepatic resection for hepatocellular carcinoma in cirrhotic liver. Langenbeck’s Arch Surg. 2010;395:625–32.CrossRef
13.
go back to reference de Haas RJ, Wicherts DA, Flores E, et al. R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery? Ann Surg. 2008;248:626–37.PubMed de Haas RJ, Wicherts DA, Flores E, et al. R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery? Ann Surg. 2008;248:626–37.PubMed
14.
go back to reference Margonis GA, Spolverato G, Kim Y, et al. Intraoperative surgical margin re-resection for colorectal liver metastasis: is it worth the effort? J Gastrointest Surg. 2015;19:699–707.CrossRefPubMed Margonis GA, Spolverato G, Kim Y, et al. Intraoperative surgical margin re-resection for colorectal liver metastasis: is it worth the effort? J Gastrointest Surg. 2015;19:699–707.CrossRefPubMed
15.
go back to reference Else T, Williams AR, Sabolch A, et al. Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 2014;99:455–61.CrossRefPubMed Else T, Williams AR, Sabolch A, et al. Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 2014;99:455–61.CrossRefPubMed
16.
go back to reference Loncar Z, Djukic V, Zivaljevic V, et al. Survival and prognostic factors for adrenocortical carcinoma: a single institution experience. BMC Urol. 2015;15:43.CrossRefPubMedPubMedCentral Loncar Z, Djukic V, Zivaljevic V, et al. Survival and prognostic factors for adrenocortical carcinoma: a single institution experience. BMC Urol. 2015;15:43.CrossRefPubMedPubMedCentral
17.
go back to reference Wanis KN, Kanthan R: Diagnostic and prognostic features in adrenocortical carcinoma: a single institution case series and review of the literature. World J Surg Oncol. 2015;13:117.CrossRefPubMedPubMedCentral Wanis KN, Kanthan R: Diagnostic and prognostic features in adrenocortical carcinoma: a single institution case series and review of the literature. World J Surg Oncol. 2015;13:117.CrossRefPubMedPubMedCentral
18.
go back to reference Margonis GA, Kim Y, Prescott JD, et al. Adrenocortical carcinoma: impact of surgical margin status on long-term outcomes. Ann Surg Oncol. 2016;23:134–41.CrossRefPubMed Margonis GA, Kim Y, Prescott JD, et al. Adrenocortical carcinoma: impact of surgical margin status on long-term outcomes. Ann Surg Oncol. 2016;23:134–41.CrossRefPubMed
19.
go back to reference Raval MV, Bilimoria KY, Stewart AK, et al. Using the NCDB for cancer care improvement: an introduction to available quality assessment tools. Journal of surgical oncology 2009;99:488–90.CrossRefPubMed Raval MV, Bilimoria KY, Stewart AK, et al. Using the NCDB for cancer care improvement: an introduction to available quality assessment tools. Journal of surgical oncology 2009;99:488–90.CrossRefPubMed
20.
go back to reference Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–9.CrossRefPubMed Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–9.CrossRefPubMed
21.
go back to reference Miller BS, Doherty GM. Surgical management of adrenocortical tumours. Nat Rev Endocrinol. 2014;10:282–92.CrossRefPubMed Miller BS, Doherty GM. Surgical management of adrenocortical tumours. Nat Rev Endocrinol. 2014;10:282–92.CrossRefPubMed
22.
go back to reference Ip JC, Pang TC, Glover AR, et al. Improving outcomes in adrenocortical cancer: an Australian perspective. Ann Surg Oncol. 2015;22:2309–16.CrossRefPubMed Ip JC, Pang TC, Glover AR, et al. Improving outcomes in adrenocortical cancer: an Australian perspective. Ann Surg Oncol. 2015;22:2309–16.CrossRefPubMed
23.
go back to reference Amini N, Margonis GA, Kim Y, et al. Curative resection of adrenocortical carcinoma: rates and patterns of postoperative recurrence. Ann Surg Oncol. 2016;23:126–33.CrossRefPubMed Amini N, Margonis GA, Kim Y, et al. Curative resection of adrenocortical carcinoma: rates and patterns of postoperative recurrence. Ann Surg Oncol. 2016;23:126–33.CrossRefPubMed
Metadata
Title
Impact of Micro- and Macroscopically Positive Surgical Margins on Survival after Resection of Adrenocortical Carcinoma
Authors
Kevin L. Anderson Jr., MHS
Mohamed A. Adam, MD
Samantha M. Thomas, MS
Linda Youngwirth, MD
Michael T. Stang, MD
Randall P. Scheri, MD
Sanziana A. Roman, MD
Julie A. Sosa, MD, MA
Publication date
01-05-2018
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 5/2018
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-018-6398-5

Other articles of this Issue 5/2018

Annals of Surgical Oncology 5/2018 Go to the issue